Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 4/20 | 0.59 |
| ▸ | PPARG | P37231 | 2/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.49 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31402270 | 1.00 | CCR2 (0.59) | CCR2PPARGBRD4AGTR1AGTR2 | |
| SCHEMBL6705831 | 0.87 | PPARG (0.47) | CCR2PPARGAGTR1AGTR2CYP19A1 | |
| SCHEMBL8687854 | 0.85 | POLB (0.53) | CCR2PPARGPOLBLMNAKDM4E | |
| SCHEMBL15700119 | 0.84 | AGTR1 (0.57) | CCR2PPARGBRD4AGTR1AGTR2 | |
| SCHEMBL4415758 | 0.83 | BRD4 (0.48) | CCR2PPARGBRD4HTTPOLB | |
| SCHEMBL30005643 | 0.80 | AGTR1 (0.53) | CCR2PPARGAGTR1AGTR2CYP19A1 | |
| SCHEMBL6211323 | 0.79 | CCR2 (0.49) | CCR2PPARGBRD4ALDH1A1 | |
| SCHEMBL4438165 | 0.79 | CCR2 (0.51) | CCR2PPARGAGTR1AGTR2CYP19A1 | |
| SCHEMBL28144657 | 0.79 | TP53 (0.52) | CCR2PPARGAGTR1AGTR2CYP19A1 | |
| SCHEMBL11390081 | 0.79 | CA12 (0.43) | CCR2PPARGAGTR1AGTR2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106928121-B | High-efficiency preparation method of 3-substituted-benzo five-membered heterocycle-2-carbonyl compound | 暨南大学 | 2020-05-12 | — | — | CN | claimed |
| CN-105732470-B | The high efficiency preparation method of 3- fluoro-indole-2-carbonyl compound | 暨南大学 | 2018-07-31 | — | — | CN | claimed |
| CN-106928121-B | High-efficiency preparation method of 3-substituted-benzo five-membered heterocycle-2-carbonyl compound | 暨南大学 | 2020-05-12 | — | — | CN | disclosed |
| US-7342039-B2 | Substituted indole oximes | WYETH (US) | 2008-03-11 | — | — | US | disclosed |
| CN-1882323-A | Substituted benzofuran oximes | WYETH CORP (US) | 2006-12-20 | — | — | CN | disclosed |
| EP-1667670-A1 | 4-(1H-INDOL-3-YL-METHYLIDENEAMINOXY-PROPOXY)-BENZOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIREMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBISIS | Wyeth (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050119326-A1 | Substituted aryloximes | WYETH (US) | 2005-06-02 | — | — | US | disclosed |
| WO-2005030192-A1 | 4- (1H-INDOL-3-YL-METHYLIDENEAMINOXY-PROPOXY) -BENZIOC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIRMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBISIS | WYETH (US) | 2005-04-07 | — | — | WO | disclosed |
| US-5811439-A | ANTIDIABETIC AGENTS; SIDE EFFECT REDUCTION; ANTILEPEMIC AGENTS | SENGA PHARMACEUTICAL LABORATORY INC. (JP) | 1998-09-22 | — | — | US | disclosed |
| CN-1167111-A | Thiazolidinedione derivatives, method for preparing derivatives and pharmaceutical compositions containing same | SENGA PHARMACEUTICAL LAB INC (JP) | 1997-12-10 | — | — | CN | disclosed |
| EP-0780389-A1 | Thiazolidinedione derivatives, process for their preparation and pharmaceutical compositions containing them | TOBISHI PHARMACEUTICAL CO., LTD. (JP) | 1997-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119326-A1 | Substituted aryloximes | IDO2, TDO2, IDO1 | CCR2 228/4885PPARG 1518/4885BRD4 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.